Summary
New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.
Scientists have developed a new, powerful medicine called sevabertinib (also known by the brand name Hyrnuo) that is helping people fight a specific type of lung cancer. This medicine is designed for patients with a rare genetic change called HER2 exon 20. While this specific mutation is only found in about 2% to 3% of lung cancer cases, it has historically been very difficult to treat because standard options like chemotherapy don’t always work well for it.
How Does the “Precision” Pill Work?
Most cancer treatments are like a “sledgehammer” that affects the whole body. However, sevabertinib is a precision medicine. Think of it like a key that only fits one specific lock. It works by finding the mutated HER2 protein in the body—which usually sends “grow” signals to cancer cells—and switching that signal off. By blocking these signals, the pill can stop the cancer from spreading or even make the tumors get smaller.
Encouraging Results
In a recent study published in the journal Cancer Discovery, the results were very exciting. In early trials, the pill shrank tumors in 70% of patients. This is a big jump from older treatments, which only worked for about half of the patients. Because the results were so good, the U.S. Food and Drug Administration (FDA) gave the drug “fast-track” approval so patients could start using it sooner.
Why This Matters
One of the best parts about this treatment is that it is a pill taken at home. Usually, cancer patients have to spend hours in the hospital getting medicine through a needle (infusion). This pill gives patients more freedom and fewer hospital visits. While it can have side effects like nausea or a rash, doctors are hopeful that this global collaboration between researchers in the U.S. and Germany will lead to even better ways to save lives in the future.
